[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-dilation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-dilation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100481197","chardonnay-marc-and-vascular-response-100481197",false,"NCT05545865","Chardonnay Marc and Vascular Response","Preclinical Trials to Determine the Range of Chardonnay Mark Intake for Improved Metabolic and Vascular Response.","Inclusion Criteria:\n\n* Screening or Visit 1 Reactive Hyperemia Index (RHI; EndoPAT 2000) \\\u003C 2.0\n* Subject is willing and able to comply with the study protocols.\n* Subject is willing to participate in all study procedures\n* BMI 25.0 - 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* BMI ≥ 35 kg\u002Fm2\n* Indivduals that weight less than a 110 lbs\n* Donation of blood within the previous 30 days\n* Visit 1 Reactive Hyperemia Index (RHI; EndoPAT 2000) ≥ 2.0\n* 1 ug\u002Fml and 3 ug\u002Fml collagen screening maximal platelet aggregatory response of \\\u003C 65%.\n* Platelet counts \\\u003C 150,000 \u002F ul\n* Anemia, which includes self report, or a screening hemoglobin and hematocrit that is less than the normal reference range or as diagnosed by study physician upon review of complete blood cell count reports.\n* Dislike or allergy for nuts, cocoa or grape products\n* Self-reported use of daily anticoagulation agents including aspirin, NSAIDs\n* Vegan, Vegetarians, food faddists or those consuming a non-traditional diet\n* Fruit consumption ≥ 3 cups\u002Fday\n* Vegetable consumption ≥ 4 cups\u002Fday\n* Nut intake ≥ 2 servings\u002F week\n* Coffee\u002Ftea ≥ 3 cups\u002Fday\n* Dark chocolate ≥ 3 oz\u002Fday\n* Self-reported restriction of physical activity due to a chronic health condition\n* Self-reported chronic\u002Froutine high intensity exercise\n* Self-reported diabetes\n* Blood pressure ≥ 140\u002F90 mm Hg\n* Self-reported renal or liver disease\n* Self-reported heart disease, which includes cardiovascular events and stroke\n* Peripheral artery disease, Raynaud's syndrome\n* Inability to properly place or wear the PAT probes or abnormal measurements on pre- screening PAT\n* Self-reported cancer within past 5 years\n* Self-reported malabsorption\n* Currently taking prescription drugs or supplements.\n* Supplement use or unwillingness to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements a month prior to study enrollment.\n* Indications of substance or alcohol abuse within the last 3 years\n* smoking, vaping, cannabis use\n* Current enrollee in a clinical research study.",true,"MALE","30 Years","50 Years",{"count":21,"type":22},5,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to obtain data on the potential influence of Vine to Bar product(s) containing Chardonnay marc on cardiometabolic health. These initial studies will inform the design and timing of data collection for future dietary intervention trials that will examine the influence of Chardonnay marc intake on outcomes\u002Fbiomarkers of both cardiometabolic health and the gut microbiome. This includes collecting data on the potential differences in response to the products based on the unique food matrix for each of the products that will be tested. Moreover, as there is a paucity of data on the influence of cocoa flavanol intake on vascular function beyond 4 hours post intake, the response of the selected outcomes will be assessed after 6 hours of flavanol intake. This is a time point that captures the increased circulating presence of microbial derived flavanol metabolites.",[28,29,30],"Cardiovascular Diseases","Vascular Dilation","Oxidative Stress","RECRUITING","2026-02-13",{"date":34,"type":35},"2026-02-18","ACTUAL",{"date":37,"type":35},"2022-09-01",{"date":39,"type":22},"2026-08-24",{"name":41,"class":42},"University of California, Davis","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100489035","a-longitudinal-study-to-identify-mechanisms-of-menopause-on-cardiovascular-disease-risk-100489035","NCT05647876","A Longitudinal Study to Identify Mechanisms of Menopause on Cardiovascular Disease Risk","Inclusion Criteria:\n\n* Normal ECG\n* Regular menstruation\n\nExclusion Criteria:\n\n* Participation in other clinical projects\n* Smokes or has smoked within the last 10 years\n* On hormone therapy\n* Has chronic diseases that are not expected, cf. the groups sought. Including heart problems, atrial fibrillation, cancer, immune diseases and previous strokes with functionally significant sequelae\n* Being treated with oral steroids\n* Has alcohol \u002F drug abuse or is being treated with disulfiram (Antabus)\n* Is unable to understand the contents of the document with informed consent or the experimental procedures\n* Pregnancy or breastfeeding\n* Systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg\n* ovariectomy\n* BMI\\>28","FEMALE","40 Years","61 Years",{"count":54,"type":22},200,"OBSERVATIONAL","With the cessation of estrogen production at menopause, the risk of cardiovascular disease like arthrosclerosis, myocardial infarction and stroke increases dramatically. Physical activity is the single most powerful \"drug\" for maintaining and improving cardiovascular health, but recent data suggest that the positive effect of physical activity is lost at menopause. In this project the investigators will follow a cohort of 200 women from before the women enter menopause and until at least 10 years past menopause. By advanced invasive methodologies the investigators will monitor the changes that occur in the blood vessels of the circulation, the heart and the brain and combine this with microRNA sequencing of blood and tissue samples.",[58,28,29,59],"Menopause","Physical Activity","2023-05-09",{"date":62,"type":35},"2023-05-10",{"date":64,"type":35},"2022-12-16",{"date":66,"type":22},"2045-08",{"name":68,"class":42},"University of Copenhagen"]